8-K: FDA Approves Abecma for Earlier Use in Triple-Class Exposed Multiple Myeloma

The FDA has approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, expanding its availability to more patients.

Summary

• The U.S. Food and Drug Administration (FDA) has approved Abecma, a CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
• This approval expands Abecma's indication, making it available earlier in the treatment journey for patients who have been exposed to three major classes of myeloma treatments.
• The approval is based on the results of the Phase 3 KarMMa-3 trial, which demonstrated a significant improvement in progression-free survival (PFS) compared to standard regimens.
• Abecma tripled the median PFS compared to standard regimens, with a median PFS of 13.3 months versus 4.4 months.
• The trial also showed a 51% reduction in the risk of disease progression or death with Abecma.
• The overall response rate was 71% for patients treated with Abecma, with 39% achieving a complete or stringent complete response, compared to 42% and 5% respectively for standard regimens.
• Abecma is administered as a one-time infusion, with a new recommended dose range of 300 to 510 x 10^6 CAR-positive T cells.
• The therapy has a well-established safety profile, with mostly low-grade cytokine release syndrome and neurotoxicity.

Sentiment

Score: 8

Explanation: The document is very positive due to the FDA approval and the significant clinical benefits demonstrated by Abecma. However, the risks associated with the treatment and the early deaths in the trial temper the overall sentiment slightly.

Positives

• Abecma's approval expands treatment options for patients with relapsed or refractory multiple myeloma.
• The therapy has shown a significant improvement in progression-free survival compared to standard regimens.
• Abecma is a one-time infusion, offering meaningful treatment-free intervals for responding patients.
• The therapy has a well-established safety profile with mostly low-grade side effects.
• The approval underscores the commitment of Bristol Myers Squibb and 2seventy bio to advancing cell therapy research.

Negatives

• There were some cases of severe side effects, including cytokine release syndrome and neurotoxicity.
• A higher proportion of patients experienced death within 9 months after randomization in the Abecma arm compared to the standard regimens arm.
• There were some cases of secondary malignancies reported following treatment with Abecma.
• Prolonged cytopenia was observed in a significant percentage of patients.

Risks

• Patients receiving Abecma are at risk of developing cytokine release syndrome (CRS), which can be severe or life-threatening.
• Neurologic toxicities, including immune-effector cell-associated neurotoxicity (ICANS), can occur following treatment with Abecma.
• Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) is a potential risk.
• Prolonged cytopenia with bleeding and infection can occur after treatment.
• There is a risk of secondary malignancies, including T-cell malignancies, following treatment with Abecma.
• Patients may experience hypersensitivity reactions, including anaphylaxis, due to DMSO in Abecma.
• Infections, including severe and fatal ones, can occur after Abecma infusion.
• Viral reactivation, such as CMV and HBV, is a potential risk.
• Hypogammaglobulinemia can occur, requiring monitoring and potential IVIG treatment.

Future Outlook

The companies plan to continue clinical studies for Abecma, including KarMMa-2, KarMMa-3, and KarMMa-9, for patients with multiple myeloma. They also aim to expand the availability of Abecma globally.

Management Comments

• Bryan Campbell, senior vice president, Head of Commercial, Cell Therapy, Bristol Myers Squibb, stated that this approval brings the promise of cell therapy to patients earlier in their treatment journey.
• Chip Baird, chief executive officer, 2seventy bio, expressed pleasure that Abecma will be available to many more patients in the U.S.

Industry Context

This approval is significant as it expands the use of CAR T-cell therapy to earlier lines of treatment for multiple myeloma, addressing a critical unmet need for patients who have relapsed or become refractory to standard therapies. It also highlights the growing importance of cell therapies in cancer treatment.

Comparison to Industry Standards

• The KarMMa-3 trial is the only Phase 3 trial to evaluate a CAR T-cell therapy in a patient population consisting entirely of triple-class exposed relapsed and refractory multiple myeloma patients.
• Abecma's median PFS of 13.3 months significantly exceeds the 3-5 months median PFS typically seen with standard regimens in this patient population.
• The 71% overall response rate and 39% complete response rate with Abecma are substantially higher than the 42% and 5% respectively achieved with standard regimens.
• Abecma is the only CAR T-cell therapy available globally for earlier lines of therapy for patients with triple-class exposed relapsed and/or refractory multiple myeloma, setting it apart from competitors such as Johnson & Johnson's Carvykti which is approved for later lines of therapy.

Stakeholder Impact

• Shareholders of 2seventy bio and Bristol Myers Squibb will likely view the FDA approval positively.
• Patients with relapsed or refractory multiple myeloma will have an additional treatment option.
• Healthcare providers will have a new therapy to offer patients.
• Employees of both companies may benefit from the commercial success of Abecma.

Next Steps

• Bristol Myers Squibb and 2seventy bio will continue to commercialize Abecma.
• The companies will continue ongoing and planned clinical studies for Abecma, including KarMMa-2, KarMMa-3, and KarMMa-9.
• They will also work to expand the availability of Abecma globally.

Key Dates

Keywords

Abecma, Multiple Myeloma, CAR T-cell therapy, FDA Approval, Bristol Myers Squibb, 2seventy bio, KarMMa-3 trial, Relapsed Refractory, Progression-Free Survival, Cell Therapy